[Development of COVID-19 drugs using human iPS cell technology]

Area of Science:

• Biomedical Research
• Stem Cell Technology
• Infectious Diseases

Background:

• Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has led to a global health crisis with increasing cases, deaths, and emergent mutant strains.
• Effective strategies against COVID-19 include vaccine development and therapeutic agents to mitigate disease severity.
• Drug repositioning offers a promising avenue for identifying existing drugs effective against COVID-19.

Purpose of the Study:

• To review recent advancements and future perspectives in COVID-19 therapeutic drug development.
• To highlight the role of human induced pluripotent stem cell (iPSC)-derived differentiated cells in evaluating drug efficacy and safety for COVID-19.
• To explore the application of iPSC technology in the search for novel anti-COVID-19 therapeutics.

Main Methods:

• Utilizing human iPSC-derived differentiated cells for drug screening and evaluation.
• Investigating drug repositioning strategies for identifying existing medications against SARS-CoV-2.
• Analyzing current research trends in COVID-19 therapeutics.

Main Results:

• Human iPSC technology provides a robust platform for assessing the efficacy and safety of potential COVID-19 drugs.
• Drug repositioning has shown potential in accelerating the development of anti-COVID-19 agents.
• The study synthesizes recent findings on therapeutic strategies for COVID-19.

Conclusions:

• Human iPSC technology is a valuable tool for advancing COVID-19 drug discovery and development.
• Continued research integrating iPSC technology and drug repositioning is crucial for combating the COVID-19 pandemic.
• Future perspectives emphasize the potential of iPSC-based approaches to overcome challenges posed by SARS-CoV-2 and its variants.